The difference between the dose achieving a therapeutic aPTT for patients with eGFR >60 when calculated by MDRD versus CG was completely abolished when obese patients were excluded from the CG cohort.
When eGFR was calculated by the modification of diet in renal disease (MDRD; ml/min/1.73 m(2)) formula, the average bivalirudin dose achieving a therapeutic aPTT was 0.07 ± 0.04, 0.12 ± 0.07, and 0.20 ± 0.07 for patients with eGFR between 15-30, 31-60, >60, respectively.
The combination showed evidence of antitumor activity, with eleven of 19 (58%) patients at the maximum tolerated dose achieving an objective response.
This confirms that, despite the potential of PRO-FIT*advice (or web-based interventions in general) to be delivered at a high dose, achieving an acceptable dose received remains challenging and less controllable.
Using a MTT cell proliferation assay we found that FLP treatment could inhibit cell proliferation in A549 cells with the low dose achieving significant inhibition; however, not to the same level of inhibition seen with CTX treatment.
However, there was a strong dose response relationship between allopurinol dose and urate concentration, with about two-thirds of patients who were on 300 mg daily dose achieving this goal.
